Logo image of CORT

CORCEPT THERAPEUTICS INC (CORT) Stock Fundamental Analysis

NASDAQ:CORT - Nasdaq - US2183521028 - Common Stock - Currency: USD

63.54  -1.55 (-2.38%)

After market: 63.54 0 (0%)

Fundamental Rating

7

Taking everything into account, CORT scores 7 out of 10 in our fundamental rating. CORT was compared to 194 industry peers in the Pharmaceuticals industry. CORT gets an excellent profitability rating and is at the same time showing great financial health properties. CORT is showing excellent growth while it is valued at reasonable prices. Keep and eye on this one! With these ratings, CORT could be worth investigating further for growth and quality investing!.


Dividend Valuation Growth Profitability Health

Quickly go to:

7

1. Profitability

1.1 Basic Checks

CORT had positive earnings in the past year.
CORT had a positive operating cash flow in the past year.
In the past 5 years CORT has always been profitable.
Each year in the past 5 years CORT had a positive operating cash flow.
CORT Yearly Net Income VS EBIT VS OCF VS FCFCORT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M 100M 150M

1.2 Ratios

CORT has a better Return On Assets (18.08%) than 98.38% of its industry peers.
With an excellent Return On Equity value of 22.20%, CORT belongs to the best of the industry, outperforming 95.14% of the companies in the same industry.
With an excellent Return On Invested Capital value of 18.79%, CORT belongs to the best of the industry, outperforming 95.14% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for CORT is significantly below the industry average of 44.04%.
Industry RankSector Rank
ROA 18.08%
ROE 22.2%
ROIC 18.79%
ROA(3y)20.33%
ROA(5y)20.48%
ROE(3y)23.7%
ROE(5y)23.34%
ROIC(3y)21.81%
ROIC(5y)22.46%
CORT Yearly ROA, ROE, ROICCORT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20 -20 40 60

1.3 Margins

CORT has a Profit Margin of 22.56%. This is amongst the best in the industry. CORT outperforms 94.59% of its industry peers.
In the last couple of years the Profit Margin of CORT has declined.
CORT's Operating Margin of 22.81% is amongst the best of the industry. CORT outperforms 88.65% of its industry peers.
In the last couple of years the Operating Margin of CORT has declined.
CORT has a Gross Margin of 98.44%. This is amongst the best in the industry. CORT outperforms 98.38% of its industry peers.
In the last couple of years the Gross Margin of CORT has remained more or less at the same level.
Industry RankSector Rank
OM 22.81%
PM (TTM) 22.56%
GM 98.44%
OM growth 3Y-15.01%
OM growth 5Y-8.99%
PM growth 3Y-9.77%
PM growth 5Y-6.02%
GM growth 3Y0.08%
GM growth 5Y0.15%
CORT Yearly Profit, Operating, Gross MarginsCORT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20 40 60 80

More info and screens

9

2. Health

2.1 Basic Checks

CORT has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
Compared to 1 year ago, CORT has less shares outstanding
Compared to 5 years ago, CORT has less shares outstanding
There is no outstanding debt for CORT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CORT Yearly Shares OutstandingCORT Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M
CORT Yearly Total Debt VS Total AssetsCORT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M

2.2 Solvency

An Altman-Z score of 30.98 indicates that CORT is not in any danger for bankruptcy at the moment.
The Altman-Z score of CORT (30.98) is better than 93.51% of its industry peers.
CORT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 30.98
ROIC/WACC1.92
WACC9.77%
CORT Yearly LT Debt VS Equity VS FCFCORT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M 500M

2.3 Liquidity

A Current Ratio of 3.70 indicates that CORT has no problem at all paying its short term obligations.
With a Current ratio value of 3.70, CORT perfoms like the industry average, outperforming 56.76% of the companies in the same industry.
A Quick Ratio of 3.64 indicates that CORT has no problem at all paying its short term obligations.
CORT's Quick ratio of 3.64 is in line compared to the rest of the industry. CORT outperforms 57.84% of its industry peers.
Industry RankSector Rank
Current Ratio 3.7
Quick Ratio 3.64
CORT Yearly Current Assets VS Current LiabilitesCORT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M

More info and screens

9

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 55.56% over the past year.
CORT shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 6.00% yearly.
CORT shows a strong growth in Revenue. In the last year, the Revenue has grown by 39.65%.
The Revenue has been growing by 13.94% on average over the past years. This is quite good.
EPS 1Y (TTM)55.56%
EPS 3Y3.78%
EPS 5Y6%
EPS Q2Q%46.43%
Revenue 1Y (TTM)39.65%
Revenue growth 3Y10.88%
Revenue growth 5Y13.94%
Sales Q2Q%47.69%

3.2 Future

Based on estimates for the next years, CORT will show a very strong growth in Earnings Per Share. The EPS will grow by 49.09% on average per year.
Based on estimates for the next years, CORT will show a very strong growth in Revenue. The Revenue will grow by 28.39% on average per year.
EPS Next Y51.12%
EPS Next 2Y50.43%
EPS Next 3Y68.8%
EPS Next 5Y49.09%
Revenue Next Year45.46%
Revenue Next 2Y30.47%
Revenue Next 3Y31.99%
Revenue Next 5Y28.39%

3.3 Evolution

The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
CORT Yearly Revenue VS EstimatesCORT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 500M 1B 1.5B 2B 2.5B
CORT Yearly EPS VS EstimatesCORT Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 2 4 6 8 10

More info and screens

5

4. Valuation

4.1 Price/Earnings Ratio

CORT is valuated quite expensively with a Price/Earnings ratio of 50.43.
CORT's Price/Earnings ratio is a bit cheaper when compared to the industry. CORT is cheaper than 80.00% of the companies in the same industry.
CORT's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 29.63.
The Price/Forward Earnings ratio is 29.56, which means the current valuation is very expensive for CORT.
Based on the Price/Forward Earnings ratio, CORT is valued a bit cheaper than 78.38% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 22.68. CORT is valued slightly more expensive when compared to this.
Industry RankSector Rank
PE 50.43
Fwd PE 29.56
CORT Price Earnings VS Forward Price EarningsCORT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, CORT is valued a bit cheaper than the industry average as 77.30% of the companies are valued more expensively.
Based on the Price/Free Cash Flow ratio, CORT is valued a bit cheaper than the industry average as 80.00% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 46.72
EV/EBITDA 42.91
CORT Per share dataCORT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
CORT has a very decent profitability rating, which may justify a higher PE ratio.
CORT's earnings are expected to grow with 68.80% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.99
PEG (5Y)8.41
EPS Next 2Y50.43%
EPS Next 3Y68.8%

More info and screens

0

5. Dividend

5.1 Amount

CORT does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CORCEPT THERAPEUTICS INC

NASDAQ:CORT (2/21/2025, 8:10:37 PM)

After market: 63.54 0 (0%)

63.54

-1.55 (-2.38%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)10-30 2024-10-30/amc
Earnings (Next)02-26 2025-02-26/amc
Inst Owners87.03%
Inst Owner Change-3.07%
Ins Owners6.48%
Ins Owner Change0.4%
Market Cap6.66B
Analysts82
Price Target76.4 (20.24%)
Short Float %17.06%
Short Ratio18.68
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)39.47%
Min EPS beat(2)36.4%
Max EPS beat(2)42.54%
EPS beat(4)4
Avg EPS beat(4)24.19%
Min EPS beat(4)6.4%
Max EPS beat(4)42.54%
EPS beat(8)6
Avg EPS beat(8)14.73%
EPS beat(12)9
Avg EPS beat(12)12.47%
EPS beat(16)12
Avg EPS beat(16)11.79%
Revenue beat(2)2
Avg Revenue beat(2)3.76%
Min Revenue beat(2)3.45%
Max Revenue beat(2)4.07%
Revenue beat(4)4
Avg Revenue beat(4)3.03%
Min Revenue beat(4)1.93%
Max Revenue beat(4)4.07%
Revenue beat(8)6
Avg Revenue beat(8)1.69%
Revenue beat(12)7
Avg Revenue beat(12)-0.35%
Revenue beat(16)8
Avg Revenue beat(16)-1.46%
PT rev (1m)0%
PT rev (3m)0.4%
EPS NQ rev (1m)13.03%
EPS NQ rev (3m)13.03%
EPS NY rev (1m)3.49%
EPS NY rev (3m)3.49%
Revenue NQ rev (1m)0.34%
Revenue NQ rev (3m)0.34%
Revenue NY rev (1m)0.14%
Revenue NY rev (3m)0.14%
Valuation
Industry RankSector Rank
PE 50.43
Fwd PE 29.56
P/S 10.59
P/FCF 46.72
P/OCF 46.04
P/B 10.42
P/tB 10.42
EV/EBITDA 42.91
EPS(TTM)1.26
EY1.98%
EPS(NY)2.15
Fwd EY3.38%
FCF(TTM)1.36
FCFY2.14%
OCF(TTM)1.38
OCFY2.17%
SpS6
BVpS6.1
TBVpS6.1
PEG (NY)0.99
PEG (5Y)8.41
Profitability
Industry RankSector Rank
ROA 18.08%
ROE 22.2%
ROCE 21.79%
ROIC 18.79%
ROICexc 44.52%
ROICexgc 44.52%
OM 22.81%
PM (TTM) 22.56%
GM 98.44%
FCFM 22.67%
ROA(3y)20.33%
ROA(5y)20.48%
ROE(3y)23.7%
ROE(5y)23.34%
ROIC(3y)21.81%
ROIC(5y)22.46%
ROICexc(3y)84.97%
ROICexc(5y)97.2%
ROICexgc(3y)84.97%
ROICexgc(5y)97.2%
ROCE(3y)25.29%
ROCE(5y)26.04%
ROICexcg growth 3Y-22.27%
ROICexcg growth 5Y-10.98%
ROICexc growth 3Y-22.27%
ROICexc growth 5Y-10.98%
OM growth 3Y-15.01%
OM growth 5Y-8.99%
PM growth 3Y-9.77%
PM growth 5Y-6.02%
GM growth 3Y0.08%
GM growth 5Y0.15%
F-Score8
Asset Turnover0.8
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 197.92%
Cap/Sales 0.33%
Interest Coverage 250
Cash Conversion 100.13%
Profit Quality 100.49%
Current Ratio 3.7
Quick Ratio 3.64
Altman-Z 30.98
F-Score8
WACC9.77%
ROIC/WACC1.92
Cap/Depr(3y)36.26%
Cap/Depr(5y)101.19%
Cap/Sales(3y)0.09%
Cap/Sales(5y)0.19%
Profit Quality(3y)128.87%
Profit Quality(5y)134.44%
High Growth Momentum
Growth
EPS 1Y (TTM)55.56%
EPS 3Y3.78%
EPS 5Y6%
EPS Q2Q%46.43%
EPS Next Y51.12%
EPS Next 2Y50.43%
EPS Next 3Y68.8%
EPS Next 5Y49.09%
Revenue 1Y (TTM)39.65%
Revenue growth 3Y10.88%
Revenue growth 5Y13.94%
Sales Q2Q%47.69%
Revenue Next Year45.46%
Revenue Next 2Y30.47%
Revenue Next 3Y31.99%
Revenue Next 5Y28.39%
EBIT growth 1Y45.99%
EBIT growth 3Y-5.76%
EBIT growth 5Y3.69%
EBIT Next Year53.38%
EBIT Next 3Y45.42%
EBIT Next 5Y26.86%
FCF growth 1Y4.95%
FCF growth 3Y-5.59%
FCF growth 5Y1.92%
OCF growth 1Y6.09%
OCF growth 3Y-5.8%
OCF growth 5Y1.89%